StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
New board member with deep oncology experience; clear near-term catalysts (IND in Q4 2026, first-in-human in Q1 2027); strong preclinical ERNA-101 data with anti-PD-1 elevates execution credibility, though clinical data remains ahead; biotech stocks often re-rate on leadership and IND milestones.
What happened, with direct paths to the underlying reporting
Ernexa Therapeutics announced the appointment of Dr. Robert Spiegel to its board as it advances ERNA-101 toward the clinic. IND-enabling work is complete with manufacturing underway, targeting an IND in Q4 2026 and first-in-human in Q1 2027. Preclinical data show ERNA-101 combined with anti-PD-1 achieving complete tumor clearance and 100% survival in an ovarian cancer model, reinforcing near-term milestones and broader oncology potential.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.